Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097344 · ClinicalTrials.gov registry record · Phase 3
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 842
- Enrollment target
NCT00097344 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics. The registered enrollment target is 842 participants.
The verdict
NCT00097344, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 842 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.
Interventions
- DRUG Letrozole
- DRUG Toremifene
- DRUG Atamestane
- DRUG Aromatase inhibition
- DRUG Estrogen receptor blocker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 842 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097344
The ClinicalTrials.gov registry entry for NCT00097344 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 842 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Letrozole is the first listed.
NCT00097344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097344 about?
NCT00097344 is a clinical study titled "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer". The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast canc...
What is the current status of trial NCT00097344?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 842 participants. The study started on 2004-12. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00097344?
The interventions under investigation include: Letrozole (DRUG), Toremifene (DRUG), Atamestane (DRUG), Aromatase inhibition (DRUG), Estrogen receptor blocker (DRUG).
Who is sponsoring clinical trial NCT00097344?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.